1. 18P Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting. (December 2022) Authors: Tarhini, A.A.; Coleman, S.S.; El Naqa, I.; Sukrithan, V.; Aakrosh, R.; McCarter, M.; Carpten, J.; Colman, H.; Ikeguchi, A.P.; Puzanov, I.; Arnold, S.; Churchman, M.L.; Hwu, P.; Conejo-Garcia, J.R.; Dalton, W.S.; Weiner, G.J.; Tan, A.C. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. (September 2015) Authors: Long, G.V.; Dummer, R.; Ribas, A.; Puzanov, I.; Michielin, O.; Vanderwalde, A.; Andtbacka, R.H.I.; Cebon, J.; Fernandez, E.; Malvehy, J.; Olszanski, A.J.; Gajewski, T.F.; Kirkwood, J.M.; Gause, C.; Chen, L.; Kaufman, D.R.; Chou, J.; Hodi, F.S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704). (September 2015) Authors: Kaufman, H.L.; Andtbacka, R.H.I.; Collichio, F.A.; Wolf, M.; Li, A.; Shilkrut, M.; Murugappan, S.; Zhao, Z.; Puzanov, I.; Ross, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S674 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3334 Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. (September 2015) Authors: Andtbacka, R.H.I.; Kaufman, H.; Collichio, F.; Amatruda, T.; Nemunaitis, J.; Chesney, J.; Puzanov, I.; Harrington, K.; Zhang, Y.; Chen, L.; Shilkrut, M.; Ross, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3340 Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: Results from the BRIM7 trial. (September 2015) Authors: Lewis, K.; Ribas, A.; Gonzalez, R.; Hamid, O.; Daud, A.; Puzanov, I.; Hsu, J.; Choong, N.; Koralek, D.; McArthur, G. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015) Authors: Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; Jalal, S.; Pant, S.; Patel, M.; Neuwirth, R.; Zohren, F.; Infante, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. (14th August 2015) Authors: Arenbergerova, M.; Fialova, A.; Gkalpakiotis, S.; Kodet, R.; Jancarkova, T.; Novotna, M.; Hess, A.; Puzanov, I.; Arenberger, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 9(2016:Sep.) Page Start: 1626 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. (February 2017) Authors: Long, G.V.; Blank, C.; Ribas, A.; Mortier, L.; Carlino, M.S.; Lotem, M.; Lorigan, P.; Neyns, B.; Petrella, T.M.; Puzanov, I.; Richtig, E.; O'Day, S.J.; Masucci, G.; Lebbe, C.; Steven, N.; Lutzky, J.; Hille, D.; Ebbinghaus, S.; Ibrahim, N.; McNeil, C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Issue 1 (21st November 2017) Authors: Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C. O.; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M. E.; LeBoeuf, N. R.; Lenihan, D.; Onofrei, C.; Shannon, V.; Sharma, R.; Silk, A. W.; Skondra, D.; Suarez-Almazor, M. E.; Wang, Y.; Wiley, K.; Kaufman, H. L. Journal: Journal for immunotherapy of cancer Issue: Volume 5:Issue 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Melanoma antigens are biomarkers for ipilimumab response. (21st September 2016) Authors: Arenberger, P.; Fialova, A.; Gkalpakiotis, S.; Pavlikova, A.; Puzanov, I.; Arenbergerova, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 2(2017) Page Start: 252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗